Di Yi Cai Jing·2025-07-14 11:58Core Viewpoint - AstraZeneca's innovative drug baxdrostat shows significant blood pressure reduction in patients with resistant hypertension, indicating a potential breakthrough in hypertension treatment [1][2] Group 1: Drug Efficacy and Research - Despite existing hypertension treatments, half of the patients do not achieve adequate blood pressure control [1] - In a late-stage trial, baxdrostat significantly lowered systolic blood pressure compared to the placebo group, achieving both primary and secondary endpoints [1] - The drug targets aldosterone, a hormone that raises blood pressure, with approximately 25% of hypertension cases linked to aldosterone level dysregulation [1] Group 2: Market Potential and Sales Forecast - AstraZeneca acquired CinCor Pharma in 2023, expanding its product line in cardiovascular and renal disease treatments with baxdrostat [1] - The company anticipates peak annual sales for baxdrostat to exceed $5 billion, with potential for use alone or in combination with Farxiga, another cardiovascular therapy [2] - Farxiga currently generates over $1 billion in annual sales, used for treating type 2 diabetes, heart failure, and chronic kidney disease [2] Group 3: Ongoing Clinical Trials - AstraZeneca is conducting a large-scale clinical study involving over 20,000 patients to test baxdrostat's efficacy across four indications, including chronic kidney disease and heart failure prevention [2] - Full trial results for baxdrostat are expected to be presented at the European Society of Cardiology (ESC) annual meeting in August [2] - China is participating in this global clinical trial [2] Group 4: Competitive Landscape - Mineralys Therapeutics is also developing a drug, lorundrostat, targeting aldosterone, with plans to submit data to the FDA by the end of the year [2]